Literature DB >> 5309463

Production and testing in the USA of influenza virus vaccine made from the Hong Kong variant in 1968-69.

R Murray.   

Abstract

The Division of Biologics Standards of the National Institutes of Health made the Hong Kong variant of influenza virus available to US manufacturers for study in August 1968 and provided them with the Aichi strain for production purposes on 9 September. The first lot of vaccine was released on 15 November; 15 million doses had been released by the peak of the epidemic, which occurred in the first week of January 1969 in the USA, and 20 million doses by the end of that month. Despite the tremendous effort made, however, it is questionable whether the use of the vaccine, necessarily in smaller quantities than the total released, had any detectable effect on the course of the 1968-69 epidemic. The author suggests that it is also doubtful whether the 1957 epidemic of Asian influenza in the USA was significantly affected by the larger amount of vaccine that was then available before the epidemic peak was reached. He stresses that priority must be given to research into the problem of making sufficient vaccine available in good time to counter a threatened influenza epidemic.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5309463      PMCID: PMC2427701     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  Developing vaccines against pandemic influenza.

Authors:  J M Wood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

2.  Comparison of the haemagglutinin production of influenza A2 Hong Kong variant and recombinant strains.

Authors:  N M Tauraso; T C O'Brien
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

3.  The benefits to all of ensuring equal and timely access to influenza vaccines in poor communities.

Authors:  Bruce Y Lee; Shawn T Brown; Rachel R Bailey; Richard K Zimmerman; Margaret A Potter; Sarah M McGlone; Philip C Cooley; John J Grefenstette; Shanta M Zimmer; William D Wheaton; Sandra Crouse Quinn; Ronald E Voorhees; Donald S Burke
Journal:  Health Aff (Millwood)       Date:  2011-06       Impact factor: 6.301

4.  Vaccination deep into a pandemic wave potential mechanisms for a "third wave" and the impact of vaccination.

Authors:  Bruce Y Lee; Shawn T Brown; Philip Cooley; John J Grefenstette; Richard K Zimmerman; Shanta M Zimmer; Margaret A Potter; Roni Rosenfeld; William D Wheaton; Ann E Wiringa; Kristina M Bacon; Donald S Burke
Journal:  Am J Prev Med       Date:  2010-11       Impact factor: 5.043

5.  Estimates of the transmissibility of the 1968 (Hong Kong) influenza pandemic: evidence of increased transmissibility between successive waves.

Authors:  Charlotte Jackson; Emilia Vynnycky; Punam Mangtani
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

6.  Fifty Years of Influenza A(H3N2) Following the Pandemic of 1968.

Authors:  Barbara J Jester; Timothy M Uyeki; Daniel B Jernigan
Journal:  Am J Public Health       Date:  2020-05       Impact factor: 9.308

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.